Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance

Chemistry and Biology

Volumn 20, Issue 9, 2013, Pages 1116-1124

  Nalam, Madhavi N L ^a   Ali, Akbar ^a   Reddy, G S Kiran Kumar ^a   Cao, Hong ^a   Anjum, Saima G ^a   Altman, Michael D ^b,c,e   Yilmaz, Nese Kurt ^a   Tidor, Bruce ^b,c   Rana, Tariq M ^a,d   Schiffer, Celia A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Massachusetts Institute of Technology   (United States)

^c Department of Electrical Engineering and Computer Science   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; VIRUS ENVELOPE; VIRUS RESISTANCE; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

DRUG DESIGN; DRUG RESISTANCE, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; KINETICS; MICROSOMES; PROTEIN BINDING; STATIC ELECTRICITY; SUBSTRATE SPECIFICITY;

EID: 84884533764     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2013.07.014     Document Type: Article

References (45)

1. A. Ali, G.S.K.K. Reddy, H. Cao, S.G. Anjum, M.N.L. Nalam, C.A. Schiffer, and T.M. Rana Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands J. Med. Chem. 49 2006 7342 7356
2. A. Ali, G.S.K.K. Reddy, M.N.L. Nalam, S.G. Anjum, H. Cao, C.A. Schiffer, and T.M. Rana Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones J. Med. Chem. 53 2010 7699 7708
3. M.D. Altman, A. Ali, G.S.K.K. Reddy, M.N.L. Nalam, S.G. Anjum, H. Cao, S. Chellappan, V. Kairys, M.X. Fernandes, and M.K. Gilson HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants J. Am. Chem. Soc. 130 2008 6099 6113
4. Y. Cai, and C.A. Schiffer Decomposing the energetic impact of drug resistant mutations in HIV-1 protease on binding DRV J. Chem. Theory Comput. 6 2010 1358 1368
5. CCP4 (Collaborative Computational Project, Number 4) The CCP4 suite: programs for protein crystallography Acta Crystallogr. D Biol. Crystallogr. 50 1994 760 763
6. M.W. Chang, and B.E. Torbett Accessory mutations maintain stability in drug-resistant HIV-1 protease J. Mol. Biol. 410 2011 756 760
7. S. Chellappan, G.S. Kiran Kumar Reddy, A. Ali, M.N.L. Nalam, S.G. Anjum, H. Cao, V. Kairys, M.X. Fernandes, M.D. Altman, and B. Tidor Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis Chem. Biol. Drug Des. 69 2007 298 313
8. T. Cihlar, G.X. He, X. Liu, J.M. Chen, M. Hatada, S. Swaminathan, M.J. McDermott, Z.Y. Yang, A.S. Mulato, and X. Chen Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring J. Mol. Biol. 363 2006 635 647
9. P. Emsley, and K. Cowtan Coot: model-building tools for molecular graphics Acta Crystallogr. D Biol. Crystallogr. 60 2004 2126 2132
10. A.K. Ghosh, K. Krishnan, D.E. Walters, W. Cho, H. Cho, Y. Koo, J. Trevino, L. Holland, and J. Buthod Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors Bioorg. Med. Chem. Lett. 8 1998 979 982
11. A.K. Ghosh, B.D. Chapsal, I.T. Weber, and H. Mitsuya Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance Acc. Chem. Res. 41 2008 78 86
12. A.K. Ghosh, S. Leshchenko-Yashchuk, D.D. Anderson, A. Baldridge, M. Noetzel, H.B. Miller, Y. Tie, Y.F. Wang, Y. Koh, I.T. Weber, and H. Mitsuya Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1′-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies J. Med. Chem. 52 2009 3902 3914
13. A.K. Ghosh, B.D. Chapsal, A. Baldridge, M.P. Steffey, D.E. Walters, Y. Koh, M. Amano, and H. Mitsuya Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation J. Med. Chem. 54 2011 622 634
14. S.V. Gulnik, and M. Eissenstat Approaches to the design of HIV protease inhibitors with improved resistance profiles Curr Opin HIV AIDS 3 2008 633 641
15. R.S. Hogg, K.V. Heath, B. Yip, K.J.P. Craib, M.V. O'Shaughnessy, M.T. Schechter, and J.S.G. Montaner Improved survival among HIV-infected individuals following initiation of antiretroviral therapy JAMA 279 1998 450 454
16. D.J. Kempf, K.C. Marsh, G. Kumar, A.D. Rodrigues, J.F. Denissen, E. McDonald, M.J. Kukulka, A. Hsu, G.R. Granneman, and P.A. Baroldi Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir Antimicrob. Agents Chemother. 41 1997 654 660
17. N.M. King, L. Melnick, M. Prabu-Jeyabalan, E.A. Nalivaika, S.S. Yang, Y. Gao, X. Nie, C. Zepp, D.L. Heefner, and C.A. Schiffer Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease Protein Sci. 11 2002 418 429
18. N.M. King, M. Prabu-Jeyabalan, E.A. Nalivaika, and C.A. Schiffer Combating susceptibility to drug resistance: lessons from HIV-1 protease Chem. Biol. 11 2004 1333 1338
19. N.M. King, M. Prabu-Jeyabalan, E.A. Nalivaika, P. Wigerinck, M.P. de Béthune, and C.A. Schiffer Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor J. Virol. 78 2004 12012 12021
20. J. Kuriyan, and W.I. Weis Rigid protein motion as a model for crystallographic temperature factors Proc. Natl. Acad. Sci. USA 88 1991 2773 2777
21. P. Kuzmič Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase Anal. Biochem. 237 1996 260 273
22. J.F. Miller, C.W. Andrews, M. Brieger, E.S. Furfine, M.R. Hale, M.H. Hanlon, R.J. Hazen, I. Kaldor, E.W. McLean, and D. Reynolds Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385 Bioorg. Med. Chem. Lett. 16 2006 1788 1794
23. W. Minor XdisplayF 1993 Purdue University West Lafayette, Indiana
24. R.J. Morris, A. Perrakis, and V.S. Lamzin ARP/wARP's model-building algorithms. I. The main chain Acta Crystallogr. D Biol. Crystallogr. 58 2002 968 975
25. G.N. Murshudov, A.A. Vagin, and E.J. Dodson Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr. D Biol. Crystallogr. 53 1997 240 255
26. S. Muzammil, P. Ross, and E. Freire A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance Biochemistry 42 2003 631 638
27. M.N.L. Nalam, and C.A. Schiffer New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors Curr Opin HIV AIDS 3 2008 642 646
28. M.N.L. Nalam, A. Ali, M.D. Altman, G.S.K.K. Reddy, S. Chellappan, V. Kairys, A. Ozen, H. Cao, M.K. Gilson, and B. Tidor Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance J. Virol. 84 2010 5368 5378
29. J. Navaza AMoRe: An automated package for molecular replacement Acta Crystallogr. A 50 1994 157 163
30. Z. Otwinowski, W. Minor, and C.W. Carter Jr. Processing of X-ray diffraction data collected in oscillation mode C.W.J. Carter, R.M. Sweet, Methods in Enzymology 1997 Academic Press New York 307 326
31. F.J. Palella Jr., K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, G.A. Satten, D.J. Aschman, S.D. Holmberg, H.I.V.O.S.I. The HIV Outpatient Study Investigators Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection N. Engl. J. Med. 338 1998 853 860
32. M. Prabu-Jeyabalan, E. Nalivaika, and C.A. Schiffer How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease J. Mol. Biol. 301 2000 1207 1220
33. M. Prabu-Jeyabalan, E. Nalivaika, and C.A. Schiffer Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes Structure 10 2002 369 381
34. K.P. Romano, A. Ali, W.E. Royer, and C.A. Schiffer Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding Proc. Natl. Acad. Sci. USA 107 2010 20986 20991
35. K.P. Romano, A. Ali, C. Aydin, D. Soumana, A. Özen, L.M. Deveau, C. Silver, H. Cao, A. Newton, and C.J. Petropoulos The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors PLoS Pathog. 8 2012 e1002832
36. V. Schomaker, and K.N. Trueblood On the rigid-body motion of molecules in crystals Acta Crystallogr. B 24 1968 63 76
37. B.R. Stranix, G. Sauvé, A. Bouzide, A. Coté, G. Sévigny, and J. Yelle Lysine sulfonamides as novel HIV-protease inhibitors: optimization of the Nepsilon-acyl-phenyl spacer Bioorg. Med. Chem. Lett. 13 2003 4289 4292
38. D.L. Surleraux, H.A. de Kock, W.G. Verschueren, G.M. Pille, L.J. Maes, A. Peeters, S. Vendeville, S. De Meyer, H. Azijn, and R. Pauwels Design of HIV-1 protease inhibitors active on multidrug-resistant virus J. Med. Chem. 48 2005 1965 1973
39. D.L. Surleraux, A. Tahri, W.G. Verschueren, G.M. Pille, H.A. de Kock, T.H. Jonckers, A. Peeters, S. De Meyer, H. Azijn, and R. Pauwels Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor J. Med. Chem. 48 2005 1813 1822
40. I.J. Tickle, and D.S. Moss Modeling rigid-body thermal motion in macromolecular crystal structure refinement IUCr99 Computing School 1999 IUCr London
41. A.M. Wensing, N.M. van Maarseveen, and M. Nijhuis Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance Antiviral Res. 85 2010 59 74
42. T.D. Wu, C.A. Schiffer, M.J. Gonzales, J. Taylor, R. Kantor, S. Chou, D. Israelski, A.R. Zolopa, W.J. Fessel, and R.W. Shafer Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments J. Virol. 77 2003 4836 4847
43. D. Xie, S. Gulnik, E. Gustchina, B. Yu, W. Shao, W. Qoronfleh, A. Nathan, and J.W. Erickson Drug resistance mutations can effect dimer stability of HIV-1 protease at neutral pH Protein Sci. 8 1999 1702 1707
44. M. Youle Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients J. Antimicrob. Chemother. 60 2007 1195 1205
45. R.K. Zeldin, and R.A. Petruschke Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients J. Antimicrob. Chemother. 53 2004 4 9